China's Sinovac Draws Criticism For Reporting H1N1 Vaccine Success
This article was originally published in PharmAsia News
Executive Summary
The claim of China's Sinovac Biotech that initial trials of its H1N1 flu vaccine were successful has drawn criticism of some foreign health officials as being precipitous. The head of the U.S. National Institute for Allergy and Infectious Diseases was among the officials who said it was impossible to evaluate Sinovac's claim of safety based on testing of only a single dose of the vaccine. He and others noted the company did not reveal the size of the dose, the amount of the virus used or if the dose was administered as a booster to the immune system. Sinovac said the single shot produced flu antibodies and side effects were similar to those resulting from a typical flu shot. (Click here for more
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.